RxDoctor Payments Data

Aileen Go, MD

Hematology & Oncology · Maywood, ILNPI 1144478421

Payments from drug & device makers

$10,057in general payments, 2019–2025

Across 37 payments — averaging $271.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Autolus Inc$5K
  • Syndax Pharmaceuticals, Inc.$4K
  • Bristol Myers Squibb$268
  • CTI Biopharma Corp.$174
  • Gilead$126
  • Heron Therapeutics, Inc.$122
  • plus $552 from 12 others

What the payments were for

  • Consulting fees$3,47535%
  • Speaking & faculty fees$4,68047%
  • Travel & lodging$1241%
  • Food & beverage$1,71317%
  • Education$651%

General payments by program year

19
20
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,057 in reported general payments places this provider in the 50th percentile of 580 hematology & oncology providers in Illinois.

See all hematology & oncology providers in Illinois

Medicare billing

Part B allowed, 2024
$44,967
Medicare patients
79
Services billed
399

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IdhifaEnasidenib Mesylate26$885,528
JakafiRuxolitinib Phosphate33$572,141
PrevymisLetermovir42$296,259
Posaconazole69$95,189
VenclextaVenetoclax42$52,257
ValacyclovirValacyclovir Hcl109$5,064
Fluconazole31$2,619
Vancomycin Hcl11$2,021
Ursodiol14$1,282
Pantoprazole Sodium75$589
Prochlorperazine Maleate12$507
Ondansetron Hcl21$317
Potassium Chloride16$179
Acyclovir15$149
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim36$100

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bristol Myers SquibbIdhifa$268$885,52826 claims
Incyte CorporationJakafi$65$572,14133 claims
MerckPrevymis$15$296,25942 claims
AbbVieVenclexta$15$52,25742 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 580 hematology & oncology providers in Illinois.

Other hematology & oncology in Maywood

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →